Holen Sie sich die Stockscreener-App
9.57
0.62%
-0.06
Handel nachbörslich:
9.57
Schlusskurs vom Vortag:
$9.63
Offen:
$9.41
24-Stunden-Volumen:
2.03M
Relative Volume:
1.07
Marktkapitalisierung:
$990.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-135.21M
KGV:
-6.6872
EPS:
-1.4311
Netto-Cashflow:
$-114.08M
1W Leistung:
-0.83%
1M Leistung:
+7.65%
6M Leistung:
-22.70%
1J Leistung:
+67.89%
1-Tages-Spanne:
$9.135
$9.64
1-Wochen-Bereich:
$9.135
$10.12
52-Wochen-Spanne:
$4.52
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.57 | 996.87M | 0 | -135.21M | -114.08M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Citigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00 - MarketBeat
ORIC Pharmaceuticals Q1 2026 Financial Report and Forward-Looking Statements - Minichart
MSN Money - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Pharmaceuticals (NASDAQ: ORIC) lifts cash to $419.7M as R&D ramps - Stock Titan
Oric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ORIC (NASDAQ: ORIC) details Q1 2026 loss and Phase 3 cancer plans - Stock Titan
Cancer drug developer picks Phase 3 dose, has cash into late 2028 - Stock Titan
BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million - TradingView
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates - GlobeNewswire
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Four new ORIC hires receive 216,000 options and 35,000 RSUs - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out | NDAQ:ORIC | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC ... - Bluefield Daily Telegraph
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
[ARS] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Pharmaceuticals (NASDAQ: ORIC) 2026 proxy details equity plan changes, director elections, auditor - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmace - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Investors to Connect - ACCESS Newswire
Oric Pharmaceuticals (ORIC) to Release Earnings on Monday - MarketBeat
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Responsive Playbooks and the ORIC Inflection - Stock Traders Daily
A Look At ORIC Pharmaceuticals (ORIC) Valuation After New Rinzimetostat AACR Prostate Cancer Data - Sahm
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Stockholders to Connect - ACCESS Newswire
Oric Pharmaceuticals (ORIC) Stock Housing Data (Grinds Higher) 2026-04-20Retail Flow - Cổng thông tin điện tử Tỉnh Sơn La
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewir - The National Law Review
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-04-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ORIC | Press Release - Stockhouse
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Sahm
ORIC Highlights Rinzimetostat's Potential at Cancer Research Mee - GuruFocus
ORIC® Pharmaceuticals Presents Preclinical Data to Support - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceutical - The National Law Review
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 105% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
ORIC stock sees biggest intraday slump in over four years – analyst says selloff 'appears exaggerated' - MSN
User - The Chronicle-Journal
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Positive Phase 1b Rinzimetostat Trial Update - Sahm
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):